Wolfgang Sadee, Dr.rer.nat.
Felts Mercer Professor of Medicine and Pharmacology
Department of Internal Medicine, Division of Human Genetics
Chair, Department of Pharmacology
Joint appointment in the Division of Human Genetics, Department of Internal Medicine
Phone: (614) 292-1597
Fax: (614) 292-7232
Pharmacogenetics-Pharmacogenomics of drug receptors and transporters, Genetics of drug addiction, other CNS disorders, cardiovascular diseases, and cancer. Chemogenomics and anticancer drug discovery.
Research conducted in the OSU Program in Pharmacogenomics aims at finding biomarkers that guide effective treatment of individual patients. We assume that genetic differences among individuals play a significant role in determining treatment outcomes. In the emerging era of personalized medicine, use of genetic information has vast promise in reducing toxicity and improving efficacy of drug therapy. This applies to drugs already in routine use and to novel drugs emerging from the discovery pipeline. While the potential of pharmacogenomics is great, translation into clinical practice has been slow.
Main hurdles in rapid implementation include the complexity of human genetics - we often do not know the impact of a gene variant on disease or therapy outcome in patients. The Sadee laboratory has developed a novel approach to finding genetic variations in key genes already know to play a significant role - either as drug targets or as disease risk factors. We have applied this approach to >60 candidate genes implicated in CNs disorders, cancer, cardiovascular disease, and inflammation and autoimmune disorders, including multiple sclerosis, and in drug metabolism. This has led to discoveries of genetic variants in key genes affecting biogenic amine activity - such as serotonin and dopamine, involved in depression, psychosis, cognition and memory, autism, neurodegenerative disorders, and drug addiction. These discoveries are all the more surprising as some of these key genes had already been under intense study elsewhere.
We have already taken these newly discovered genetic markers into clinical trials, finding unexpectedly strong association in some cases, and raising the hope for the development of viable biomarkers. We are currently initiating a series of clinical collabortions, addressing the following medical needs and searching for potential biomarkers/drug targets: cancer (e.g., colon, lung, breast), hypertension and myocardial infarction, CNS disorders, including drug addiction, and HIV/AIDS.
M.Pharmacy, Freie Universitat Berlin, Pharmacy, 1966
Dr.rer.nat., Freie Universitat Berlin, Pharmaceutical Chemistry, 1968